Another small molecule, APR-246 targeting mutated p53 has been studied in clinical trials in esophageal adenocarcinoma or SCC in combination with neoadjuvant chemotherapies fluorouracil and cisplatin, which are used also in treatment of non-curable cSCC tumors [174,175,176]. This evidence concerns the gene TP53 and skin squamous cell carcinoma.